| DUR | drug use review; drug utilization review |
|---|---|
| IVDA/IVDU | intravenous drug abuse/ abuser; intravenous drug use/user |
| Rx | drug; medication; pharmacy; prescribe, prescription, prescription drug; take [Lat. recipe]; therapy;... |
| AMI | Acute Myocardial Infarction - Complications(Cx) 1. Early ... |
| AR | 1) Aortic Regurgitation = AI Echo소견 &... |
| evoked response | An alteration in the electrical activity of a region of the nervous system through which an incoming sensory stimulus is passing; may be somatosensory (SER), auditory (BAER), or visual (VER). See: evoked potential. (05 Mar 2000) |
|---|---|
| evoked response audiometry | A type of electrophysiologic audiometry in which electrical potentials of neural impulses from the cochlear nerve and various levels in the brain in response to acoustic stimulation are used to localise the site of a lesion causing a hearing loss. (05 Mar 2000) |
| unconditioned response | A response, such as salivation, which is a part of the animal or human repertoire. Compare: conditioned response. (05 Mar 2000) |
| flight or fight response | See: emergency theory. (05 Mar 2000) |
| late-phase response | Recurrence of symptoms after an appreciable interval following challenge with an antigen; preceded by an initial early-phase response. (05 Mar 2000) |
| lh response to gnrh | This test measures the level of luteinising hormone in the blood after an injection of gonadotrophin releasing hormone (GNRH), normally produced in the hypothalamus. This will test the ability of the pituitary gland to respond by measuring one of the pituitary glands byproducts, luteinising hormone. This test is used to differentiate hypogonadism (ovary or testes) into primary hypogonadism (problem is with the ovary or testes) or secondary hypogonadism (problem is with the pituitary gland or the hypothalamus). (27 Sep 1997) |
| lymphoproliferative response | <haematology, immunology> A specific immune response that entails rapid T-cell replication. Standard antigens, such as tetanus toxoid, that elicit this response are used in lab tests of immune competence. (13 Nov 1997) |
| abnormalities, drug-induced | Congenital abnormalities caused by medicinal substances or drugs of abuse given to or taken by the mother, or to which she is inadvertently exposed during the manufacture of such substances. The concept excludes abnormalities resulting from exposure to non-medicinal chemicals in the environment. (12 Dec 1998) |
| activity, drug | A measure of the physiological response a drug produces in the body. A less active drug produces less response (and visa versa). (12 Dec 1998) |
| addictive drug | Any drug that creates a certain degree of euphoria and has a strong potential for addiction. (05 Mar 2000) |
| adverse drug reaction reporting systems | Systems developed for collecting reports from government agencies, manufacturers, hospitals, physicians, and other sources on adverse drug reactions. (12 Dec 1998) |
| akathisia, drug-induced | Motor restlessness with sensations of quivering and an urge to move about constantly resulting from the use of certain drugs, such as neuroleptic drugs, which affect the extrapyramidal region of the brain. This differs from dyskinesia, drug-induced in that long-term antipsychotic drug exposure is significantly correlated with the increased prevalence of akathisia while there is no such correlation with dyskinesia. The primary observable distinction between tardive akathisia and dyskinesia appears to be in the repetitive, stereotypy of the dyskinesic movements (lip smacking, for example), while akathisia is associated with anxiety, restlessness, and agitation (psychomotor agitation). (12 Dec 1998) |
| antineoplastic drug | A drug that stops or slows the maturation and spread of tumour cells (benign or malignant). (09 Oct 1997) |
| maintenance drug therapy | In chemotherapy, systematic dosage at a level that maintains protection against exacerbation. (05 Mar 2000) |
| rational drug design | <pharmacology> Modeling the molecular structure of the target of a drug, for example, an antigen, and then designing a drug that will attack it. (17 Dec 1997) |